Here we report a Phase II study evaluating the safety and preliminary anti-tumor activity of the mIDH1 inhibitor ivosidenib plus the anti-PD1 antibody nivolumab in patients with mIDH1 advanced solid tumors, as well as associated pharmacodynamic, serum and tumor based translational correlates. The gene discussed is PDCD1; the disease is neoplasm.